Pallas Health review
Prices both molecules openly and bills them in 12-week blocks — $597 and $897 up front, with no monthly option to fall back on.
- Semaglutide
- $199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks
- Tirzepatide
- $299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks
- Coverage
- Most states
- Brand-name
- Compounded only
Semaglutide · modeled / year
$2,388
Tirzepatide · modeled / year
$3,588
Pricing verified August 2026
The Index scorecard
Pallas Health scored on our six Cost-Efficiency Index factors. See the methodology.
Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
- The reduced first cycle is an intro rate; the standing block is what you pay from the second cycle on
- Compounded semaglutide and tirzepatide are not FDA-approved products
The bottom line
Best for: Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit. Prices both molecules openly and bills them in 12-week blocks — $597 and $897 up front, with no monthly option to fall back on.
Ranked #42 of 529 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.
Compare with other providers
All 528 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Pallas Health.
- #45NiceRx— NiceRx is a compounded GLP-1 telehealth platform charging $199/mo for semaglutide and $299/mo for tirzepatide on an ongoing month-to-month basis (first month discounted to $99 and $199 respectively).76/100
- #46Vytora Health— Vytora Health (Wasef Health, PC) is a 50-state-plus-DC telehealth platform selling flat-rate compounded semaglutide and tirzepatide alongside retail-priced brand-name Mounjaro and Zepbound ($1,399/mo each).76/100
- #47Rylo Health— Rylo Health is a compounded GLP-1/NAD+/peptide telehealth platform operating in all 50 states through Lone Star Virtual Health PLLC and dispensing via VialsRX in Houston, TX.75/100
- #48Synergy Rx— Brand Wegovy, Ozempic or Mounjaro when clinically appropriate, with unlimited round-the-clock clinical contact — at prices its own site never shows.72/100
- #49Peter MD— One account across six verticals — TRT, ED, weight loss, GLP-1, men's hair loss and NAD+ — from a physician-prescribed telehealth brand running since 2021, at a renewal price ($249/mo tirzepatide) well above its own $149 first-month headline.72/100
- #50EdgeRx— The best clinical documentation of any newly added row — a named Chief Medical Advisor and a named 503A pharmacy — but it's a men's-only platform, not a fit for every reader.74/100
The 18 programs nearest this one
Pricing, states and verification reflect Pallas Health's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Pallas Health's site. Not medical advice; see our disclosure.